Innovations + Investments in Healthcare Summit 2015

Breaking World Pharma News

Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments

NovartisNovartis announced has entered into a global collaboration with Amgen to commercialize and develop pioneering neuroscience treatments. The companies will partner in the development and commercialization of a BACE inhibitor program in Alzheimer's Disease (AD). Novartis' oral therapy CNP520 will be the lead molecule and further compounds from both company's pre-clinical BACE inhibitor programs may be considered as follow-on molecules.


AstraZeneca and Valeant Pharmaceuticals to partner on brodalumab

AstraZenecaAstraZeneca has entered into a collaboration agreement with Valeant Pharmaceuticals International, Inc. under which it will grant an exclusive license for Valeant to develop and commercialise brodalumab. Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis.


Midday naps associated with reduced blood pressure and fewer medications

Midday naps are associated with reduced blood pressure levels and prescription of fewer antihypertensive medications, according to research presented at ESC Congress by Dr Manolis Kallistratos, a cardiologist at Asklepieion Voula General Hospital in Athens, Greece. The purpose of this prospective study was to assess the effect of midday sleep on blood pressure (BP) levels in hypertensive patients.


A healthy environment can prevent heart disease

Cardiovascular diseases (CVD), including heart disease and stroke, are the number 1 killer worldwide and in Europe, where they cause the death of over 10 000 people daily, i.e. more than all cancers combined (1). Recent scientific evidence shows that air and noise pollution are environmental health risks which have severe consequences on heart health (2-5).


Novo Nordisk plans 2 billion US dollar investment in new production facilities in Clayton, North Carolina and Måløv, Denmark

Novo NordiskNovo Nordisk plans to invest an estimated 2 billion US dollars over the next five years in new production facilities in Clayton, North Carolina, US and Måløv, Denmark. The expansions will help Novo Nordisk meet the increasing worldwide demand for its diabetes medicines.


Adverse effects of common prostate enlargement and hair growth drugs

Twenty-five percent of men currently taking Finasteride or Dutasteride, popularly known as Proscar and Avodart, for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss (known as alopecia) are also at risk for adverse events elicited by these drugs.


Scientists discover electrical control of cancer cell growth

The molecular switches regulating human cell growth do a great job of replacing cells that die during the course of a lifetime. But when they misfire, life-threatening cancers can occur. Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.


World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]